CoChat

Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial

Open access
Abdallah, Chadi G., Roache, John D., Averill, Lynnette A., Young-McCaughan, Stacey, Martini, Brenda, Gueorguieva, Ralitza, Amoroso, Timothy, Southwick, Steven M., Guthmiller, Kevin, López-Roca, Argelio L., Lautenschlager, Karl, Mintz, Jim, Litz, Brett T., Williamson, Douglas E., Keane, Terence M., Peterson, Alan L., Krystal, John H. · 2019 · Contemporary Clinical Trials
Cited by 33

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Posttraumatic stress disorder (PTSD) is a debilitating disorder with limited medication treatment options. Recent reports have described the dearth of research on new drug development as a crisis in the pharmacotherapy of PTSD. There are only two PTSD medications approved by the U.S. Food and Drug Administration, and both are serotonergic antidepressants. Therefore, there is a tremendous need to identify more effective and more rapidly acting pharmacotherapies for PTSD that work through novel neural mechanisms. Pilot evidence and case reports provided preliminary evidence supporting the safety and utility of investigating the therapeutic effects of ketamine in PTSD. However, the efficacy of this drug for PTSD has not yet been tested in active duty military or veteran populations. Here, we report the design and methods of a study funded under the Consortium to Alleviate PTSD. The study is a multisite, placebo-controlled, double-blind, randomized clinical trial to examine the dose-related efficacy of ketamine, as compared to placebo, in producing a rapid and sustained reduction in PTSD symptomatology in veterans and active duty military populations with antidepressant-resistant PTSD. Approximately 198 eligible participants who meet criteria for PTSD will be randomized to the study drug (i.e., ketamine 0.5 mg/kg, ketamine 0.2 mg/kg, or placebo). The study drug will be administered intravenously twice per week for 4 weeks, followed by a 4-week follow-up period. This ongoing study is the only trial of therapeutic effects of ketamine for PTSD and the first placebo-controlled trial to determine the dose-related effects of repeated ketamine on PTSD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cct.2019.04.009

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 33

Metadata

Authors
Abdallah, C. G., Roache, J. D., Averill, L. A., Young-McCaughan, S., Martini, B., Gueorguieva, R., Amoroso, T., Southwick, S. M., Guthmiller, K., López-Roca, A. L., Lautenschlager, K., Mintz, J., Litz, B. T., Williamson, D. E., Keane, T. M., Peterson, A. L., & Krystal, J. H.
Venue
Contemporary Clinical Trials
Publisher
Elsevier BV
Published
2019-06
Volume
81
Pages
11-18
ISSN
1551-7144 (ISSN-L)
OpenAlex
W2937594981
Cited by
33
References
16
FWCI
5.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1016/j.cct.2019.04.009
The paper
Abdallah, C. G., Roache, J. D., Averill, L. A., Young-McCaughan, S., Martini, B., Gueorguieva, R., Amoroso, T., Southwick, S. M., Guthmiller, K., López-Roca, A. L., Lautenschlager, K., Mintz, J., Litz, B. T., Williamson, D. E., Keane, T. M., Peterson, A. L., & Krystal, J. H. (2019). Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2019.04.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.